- Home
- BRN vs NCNA Comparison
BRN vs NCNA Comparison
Compare BRN & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRN | NCNA |
|---|---|---|
| Founded | 1956 | 1997 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 8.8M |
| IPO Year | 1995 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BRN | NCNA |
|---|---|---|
| Price | $1.09 | $1.91 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 361.1K | 29.8K |
| Earning Date | 06-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,697,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $0.03 |
| 52 Week High | $2.28 | $10.00 |
Technical Indicators
Market Signals| Indicator | BRN | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 49.36 | 36.81 |
| Support Level | N/A | $0.05 |
| Resistance Level | $1.32 | $2.27 |
| Average True Range (ATR) | 0.14 | 0.16 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 28.57 | 18.42 |
Price Performance
Historical ComparisonAbout BRN Barnwell Industries Inc.
Barnwell Industries Inc is an oil and gas company engaged in the acquisition, development, production, and sale of crude oil and natural gas. The Company operates through two segments: the Oil and Natural Gas segment, which focuses on oil and natural gas development, production, acquisitions, and sales in the United States and Canada; and the Land Investment segment, which owns leasehold land interests in Hawaii. The Company generates the majority of its revenue from the Oil and Natural Gas segment. The company operates in two geographic regions, the United States and Canada, with Canada contributing the majority of revenue.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.